Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy

Gamma delta T cells (γδT) are potent mediators of antitumor cytotoxicity and have shown promising efficacy in early phase clinical trials. Most is known about the tumoricidal properties of cells bearing the Vδ2 T cell receptor chain, but recent studies have demonstrated that cells with the Vδ1 chain...

Descripción completa

Detalles Bibliográficos
Autores principales: Fisher, Jonathan, Kramer, Anne-Marijn, Gustafsson, Kenth, Anderson, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404791/
https://www.ncbi.nlm.nih.gov/pubmed/25949890
http://dx.doi.org/10.4161/2162402X.2014.973808
_version_ 1782367553882947584
author Fisher, Jonathan
Kramer, Anne-Marijn
Gustafsson, Kenth
Anderson, John
author_facet Fisher, Jonathan
Kramer, Anne-Marijn
Gustafsson, Kenth
Anderson, John
author_sort Fisher, Jonathan
collection PubMed
description Gamma delta T cells (γδT) are potent mediators of antitumor cytotoxicity and have shown promising efficacy in early phase clinical trials. Most is known about the tumoricidal properties of cells bearing the Vδ2 T cell receptor chain, but recent studies have demonstrated that cells with the Vδ1 chain and those with neither Vδ1 nor Vδ2 chains have properties which may make them more attractive anticancer effectors in adoptive immunotherapy.
format Online
Article
Text
id pubmed-4404791
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-44047912015-12-23 Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy Fisher, Jonathan Kramer, Anne-Marijn Gustafsson, Kenth Anderson, John Oncoimmunology Author's View Gamma delta T cells (γδT) are potent mediators of antitumor cytotoxicity and have shown promising efficacy in early phase clinical trials. Most is known about the tumoricidal properties of cells bearing the Vδ2 T cell receptor chain, but recent studies have demonstrated that cells with the Vδ1 chain and those with neither Vδ1 nor Vδ2 chains have properties which may make them more attractive anticancer effectors in adoptive immunotherapy. Taylor & Francis 2014-12-23 /pmc/articles/PMC4404791/ /pubmed/25949890 http://dx.doi.org/10.4161/2162402X.2014.973808 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Author's View
Fisher, Jonathan
Kramer, Anne-Marijn
Gustafsson, Kenth
Anderson, John
Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy
title Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy
title_full Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy
title_fullStr Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy
title_full_unstemmed Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy
title_short Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy
title_sort non-v delta 2 gamma delta t lymphocytes as effectors of cancer immunotherapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404791/
https://www.ncbi.nlm.nih.gov/pubmed/25949890
http://dx.doi.org/10.4161/2162402X.2014.973808
work_keys_str_mv AT fisherjonathan nonvdelta2gammadeltatlymphocytesaseffectorsofcancerimmunotherapy
AT kramerannemarijn nonvdelta2gammadeltatlymphocytesaseffectorsofcancerimmunotherapy
AT gustafssonkenth nonvdelta2gammadeltatlymphocytesaseffectorsofcancerimmunotherapy
AT andersonjohn nonvdelta2gammadeltatlymphocytesaseffectorsofcancerimmunotherapy

Ejemplares similares